TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8123409

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Thiopentone 2 mg kg‐1 + Suxamethonium 1 mg kg‐1
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg kg‐1 + Suxamethonium 1 mg kg‐1
Number of subjects: 43

Group type: COMPARATOR
Intervention: No thiopentone or suxamethonium (group N)
Number of subjects: 43
Study: 3541813

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 80
Study: 31899928

Group type: EXPERIMENTAL
Intervention: TORA training during NRP course
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard NRP course (control)
Number of subjects: 65
Study: 31751354

Group type: EXPERIMENTAL
Intervention: Counter Strike: Global Offensive
Number of subjects: 18
Study: 27865532

Group type: EXPERIMENTAL
Intervention: Tarp-assisted cooling (water temperature 9.20°C)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Passive cooling in a climatic chamber
Number of subjects: 2
Study: 26685030

Group type: EXPERIMENTAL
Intervention: Postoperative adipose derived mesenchymal stem cell treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Arthroscopic microfracture alone (control group)
Number of subjects: 40
Study: 22776420

Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Trauma controls (TCs)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 45
Study: 21873086

Group type: EXPERIMENTAL
Intervention: MTAD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 45
Study: 18266604

Group type: EXPERIMENTAL
Intervention: HGS004 (40 mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: HGS004 (8, 20, and 40 mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: HGS004 (0.4-40 mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: HGS004
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17304769

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (TH-I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conservative rehabilitation (TH-C)
Number of subjects: 45
Study: 15541412

Group type: EXPERIMENTAL
Intervention: ACIDFORM administered 0‐30 min precoitus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACIDFORM given 8‐10 h precoitus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% nonoxynol‐9 (N‐9) product administered 0‐30 min precoitus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycles (no treatment)
Number of subjects: 20
Study: 11416735

Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruptions (STI)
Number of subjects: 10
Study: 9285375

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intranasal placebo (0.9% NaCl) followed by intravenous midazolam (0.05 mg/kg)
Number of subjects: 40
Study: 8417420

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study: 3734847

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy
Number of subjects: 12
Study: 31544519

Group type: EXPERIMENTAL
Intervention: Descriptive norm messaging with haptic input
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no descriptive norm messaging)
Number of subjects: 0
Study: 30156200

Group type: EXPERIMENTAL
Intervention: SRP followed by Er, Cr: YSGG laser treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study: 26363048

Group type: EXPERIMENTAL
Intervention: mCare mobile application
Number of subjects: 95
Study: 25093276

Group type: EXPERIMENTAL
Intervention: Diet combining lower carbohydrate content and glycemic index (GI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diet combining higher carbohydrate content and glycemic index (GI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diets varying in protein content and glycemic index
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controlled lab study with four diets differing in carbohydrate content and glycemic index
Number of subjects: 25
Study: 22718189

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria (1.48%)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal albuminuria (27.4%)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Microalbuminuria (27.2%)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Podocyte detachment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Endothelial cell fenestration
Number of subjects: 37
Study: 21092500

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve blockade (CFNB) with ropivacaine 0.2% (median infusion rate 5 ml/h)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Continuous intravenous analgesia (CIA) with fentanyl 30 µg/kg (2 ml/h)
Number of subjects: 126
Study: 19012865

Group type: EXPERIMENTAL
Intervention: Susceptibility testing for AD with APOE epsilon 4+
Number of subjects: 123

Group type: COMPARATOR
Intervention: Deterministic genetic testing (positive results)
Number of subjects: 123
Study: 16422868

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12902634

Group type: EXPERIMENTAL
Intervention: Intermittent high-permeability hemofiltration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional hemofiltration
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-permeability filtrates
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional filtrates
Number of subjects: 28
Study: 11381293

Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis using basic fibroblast growth factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis using human vascular endothelial growth factor
Number of subjects: 0
Study: 9142006

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7704492

Group type: EXPERIMENTAL
Intervention: Teicoplanin and aztreonam (antibiotic prophylaxis)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study: 3555429

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 0
Study: 29154650

Group type: EXPERIMENTAL
Intervention: Chicago School Readiness Project (CSRP) preschool intervention
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 602
Study: 25386694

Group type: EXPERIMENTAL
Intervention: e-learning course
Number of subjects: 98

Group type: COMPARATOR
Intervention: lecture-based course
Number of subjects: 98
Study: 24743455

Group type: EXPERIMENTAL
Intervention: Aqua lymphatic therapy (ALT) combined with home-based exercise (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Home-based exercise alone (control group; n = 12)
Number of subjects: 25
Study: 23354227

Group type: EXPERIMENTAL
Intervention: Cryopreserved RBCs
Number of subjects: 57

Group type: COMPARATOR
Intervention: Refrigerated RBCs
Number of subjects: 57
Study: 21353109

Group type: EXPERIMENTAL
Intervention: Prednisone (administered orally for 4 weeks before IUI)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Antibody-negative group
Number of subjects: 98
Study: 18808400

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 16670077

Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (epoietin) + granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 12814500

Group type: EXPERIMENTAL
Intervention: Reduction message
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Side-effects message
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Temporary abstinence message
Number of subjects: 2027
Study: 10836911

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous ardeparin (100 anti‐Xa IU/kg of body weight)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study: 8780079

Group type: EXPERIMENTAL
Intervention: Zalcitabine monotherapy (2.25 mg/day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination therapy (2.25 mg/day ddC with zidovudine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 79
Study: 1345754

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 212

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 212
Study: 31638608

Group type: EXPERIMENTAL
Intervention: Pregabalin (1 mg/kg of weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28132867

Group type: EXPERIMENTAL
Intervention: 75 mg GS-9256 BID
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 300 mg GS-9256 QD
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 200 mg GS-9256 BID
Number of subjects: 54

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study: 25424973

Group type: EXPERIMENTAL
Intervention: Positive psychology interventions (random assignment to one out of nine interventions)
Number of subjects: 165
Study: 24392703

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 27
Study: 21543993

Group type: COMPARATOR
Intervention: 0.03% mitomycin C (MMC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg in 0.05 mL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bevacizumab soaked in sponges (1.25 mg in 0.05 mL)
Number of subjects: 38
Study: 19733018

Group type: EXPERIMENTAL
Intervention: Dronabinol (oral ingestion of therapeutic THC)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Illicit plant cannabis product (smoking)
Number of subjects: 117
Study: 17717037

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 22

Group type: COMPARATOR
Intervention: Medical management with thrombolytic drugs
Number of subjects: 22
Study: 16379317

Group type: EXPERIMENTAL
Intervention: TURN treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BCG therapy (6 intravesical instillations of Onko BCG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 12509214

Group type: EXPERIMENTAL
Intervention: Allogeneic red blood cells (n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Predeposited autologous whole blood transfusion (n = 16)
Number of subjects: 31
Study: 9609216

Group type: EXPERIMENTAL
Intervention: Nadroparin (20,500 AXa IU/ml) once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nadroparin (10,250 AXa IU/ml) twice daily
Number of subjects: 0
Study: 7891796

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional drugs
Number of subjects: 73
Study: 2226079

Group type: EXPERIMENTAL
Intervention: Direct current therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bipolar diathermy
Number of subjects: 50
Study: 389265

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Bacille Calmette‐Guérin vaccine (BCG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 32
Study: 31318176

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 0
Study: 28917544

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg)
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Sulfonylureas (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide)
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 3028
Study: 25775445

Group type: EXPERIMENTAL
Intervention: Single injection of 25 U of BoNT‐A to the masseter muscle bilaterally (Group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two sessions of 25 U of BoNT‐A to the masseter muscle bilaterally (Group II)
Number of subjects: 20
Study: 23720105

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 96
Study: 21746787

Group type: EXPERIMENTAL
Intervention: C+P (25 g carbohydrate + 10 g whey protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CHO (25 g carbohydrate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C+P
Number of subjects: 10

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 10
Study: 19309533

Group type: EXPERIMENTAL
Intervention: Approaching targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoiding targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model simple and complex cells responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gaze direction
Number of subjects: 0
Study: 16952635

Group type: EXPERIMENTAL
Intervention: 75 mg tramadol/650 mg acetaminophen orally plus periprostatic 1% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus periprostatic 1% lidocaine
Number of subjects: 60
Study: 15252826

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for the first 4 weeks and 10 mg/day for the following 4 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11236074

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paroxetine and Sertraline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with first depression
Number of subjects: 30
Study: 9294750

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cervical Collar
Number of subjects: 81
Study: 8420311

Group type: EXPERIMENTAL
Intervention: Transdermally administered 17 beta‐estradiol
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 3736737

Group type: COMPARATOR
Intervention: Ibopamine, 200 mg and 600 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indoramin, 50 mg
Number of subjects: 20
Study: 31810613

Group type: COMPARATOR
Intervention: PMMA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: POM
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 21
Study: 28657911

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 38
Study: 27098150

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 6098

Group type: COMPARATOR
Intervention: Trastuzumab/Lapatinib combination
Number of subjects: 6098
Study: 26238121

Group type: EXPERIMENTAL
Intervention: Roxadustat 0.7 mg/kg BIW
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Roxadustat 1.0 mg/kg BIW
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Roxadustat 1.5 mg/kg BIW
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Roxadustat 2.0 mg/kg BIW
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Roxadustat 2.0 mg/kg TIW
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 23445604

Group type: EXPERIMENTAL
Intervention: 6-week self-management workshop
Number of subjects: 134

Group type: COMPARATOR
Intervention: Information-only intervention
Number of subjects: 134
Study: 21123458

Group type: EXPERIMENTAL
Intervention: 550 mg choline/d
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1100 mg choline/d
Number of subjects: 23
Study: 18355770

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 16310388

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 529

Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg twice daily
Number of subjects: 529
Study: 14567443

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (11/h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 16
Study: 10854867

Group type: EXPERIMENTAL
Intervention: Speculoscopy
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Acetic Acid Test (AAT)
Number of subjects: 1150
Study: 9088581

Group type: EXPERIMENTAL
Intervention: 160 mg sotalol alone (phase 1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 160 mg sotalol plus 20 ml of antacid (phase 2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 160 mg sotalol plus antacid given 2 h after sotalol (phase 3)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Combined administration of sotalol and MAH
Number of subjects: 6
Study: 1441789

Group type: EXPERIMENTAL
Intervention: 200 mg recombinant human SOD (rh-SOD) administered intravenously 10-20 minutes prior to reperfusion
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 3510232

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 31295334

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection with P. falciparum sporozoites (Sanaria PfSPZ Challenge)
Number of subjects: 20
Study: 28150972

Group type: EXPERIMENTAL
Intervention: Experimental condition - training to approach alternative activities and avoid smoking-related targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition - equal pushing and pulling of smoking and alternative activity-related targets
Number of subjects: 0
Study: 26403133

Group type: EXPERIMENTAL
Intervention: Triclosan-coated Vicryl Plus
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vicryl (uncoated)
Number of subjects: 17
Study: 23651789

Group type: EXPERIMENTAL
Intervention: Topical diacerein 1%
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 22185067

Group type: EXPERIMENTAL
Intervention: Stride Rite athletic shoes
Number of subjects: 12

Group type: COMPARATOR
Intervention: flip flop sandals
Number of subjects: 12
Study: 19244158

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT) with sibling donor (sib)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT) with matched unrelated donor (MUD)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Matched sibling donor availability
Number of subjects: 267
Study: 17947606

Group type: EXPERIMENTAL
Intervention: rhGH + parenteral nutrition (PN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: parenteral nutrition (PN)
Number of subjects: 24
Study: 15036719

Group type: EXPERIMENTAL
Intervention: 100mg methylprednisolone + 3mg granisetron
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 200mg methylprednisolone + 3mg granisetron
Number of subjects: 64
Study: 14723439

Group type: EXPERIMENTAL
Intervention: Strength-focused pre-intake form
Number of subjects: 88

Group type: COMPARATOR
Intervention: Problem-focused pre-intake form
Number of subjects: 88
Study: 9434647

Group type: EXPERIMENTAL
Intervention: Multidisciplinary dietary intervention over 3 years, teaching a diet low in total fat, saturated fat, and cholesterol, and high in polyunsaturated fat.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual-care (control) group, no specific intervention mentioned.
Number of subjects: 334
Study: 7801186

Group type: EXPERIMENTAL
Intervention: Meta-analysis of low back pain literature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analytic methods
Number of subjects: 0
Study: 3122554

Group type: EXPERIMENTAL
Intervention: Milk-based food supplement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milk-based food supplement plus breakfast meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lactose solution (control)
Number of subjects: 12
Study: 4596406

Group type: EXPERIMENTAL
Intervention: Trimethoprim sulfamethoxazole
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sulfamethoxazole alone
Number of subjects: 39
Study: 31181140

Group type: EXPERIMENTAL
Intervention: Overlapping (O) border
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Approximating (A) border
Number of subjects: 15
Study: 28375640

Group type: EXPERIMENTAL
Intervention: Coriolus versicolor (CV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26790206

Group type: EXPERIMENTAL
Intervention: Acupuncture at single point (Bailao - EX-HN 15)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Acupuncture at multiple points (Bailao - EX-HN 15 and Hegu - LI 4)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (19 healthy people)
Number of subjects: 49
Study: 23662822

Group type: EXPERIMENTAL
Intervention: Global brain atrophy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Older age, male sex, and systemic inflammatory response syndrome (SIRS)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Brain atrophy
Number of subjects: 97
Study: 20196640

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) - estradiol and progestogen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with tamoxifen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75